A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis

Summary

This study is a single-center, randomized, double-blind, multiple ascending doses (MAD), placebo-controlled phase Ib/IIa clinical trial of BGT-002 Tablets in subjects with NASH to evaluate the safety, tolerability, pharmacokinetics (PK) and early pharmacodynamics (PD) of BGT-002 Tablets.

Timeline

Start

2023-03-21

Primary completion

2024-03-04

Completion

2024-03-04

Drugs

Indications